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opioid dose of q50 mg oral morphine equivalents/day for q2 weeks and 3 rescue-free 
bowel movements (RFBMs)/week. Rescue laxative use was standardized and allowed 
if needed. Patients completed EQ-5D questionnaire on day 14 and day 28. EQ-5D 
index scores were compared between treatment and placebo groups using analysis of 
covariance, with treatment group as factor and baseline scores as covariate. RESULTS: 
Majority of the patients in the study were female (60%), Caucasian (90%), average 
age of 49 years and back pain (60%) was the most frequently reported pain condition. 
The mean daily baseline morphine equivalent opioid dose was 222 mgs. The mean o 
SD baseline EQ-5D index scores were 0.45 o 0.33 in QD, 0.47 o 0.33 in QOD and 
0.44 o 0.35 in placebo groups respectively. The adjusted mean (o SE) change from 
baseline in index score on day 14 in QD (0.04 o 0.02) and QOD groups (0.06 o 0.02) 
were not statistically signiﬁcant compared to placebo (0.02 o 0.02). At the end of 
the double blind period (day 28), a signiﬁcantly greater change from baseline in 
index scores was detected in the Methylnaltrexone QD dosing group (0.08 vs. 0.01; 
p  0.05) and QOD dosing group (0.08 Vs. 0.01; p  0.05) compared to placebo. 
CONCLUSIONS: Methylnaltrexone SC QD and QOD groups showed a signiﬁcantly 
greater improvement in health related quality of life as measured by the EQ-5D index 
scores at the end of four weeks of therapy compared to placebo.
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OBJECTIVES: Diagnostic self-administered questionnaires for GERD are widely used        
and provide brief and valid measure of gastrointestinal symptoms. Beyond evaluation 
of symptoms and disease severity they are considered as proxy for Quality of Life 
(QoL) and other patients related outcome. Present study should examine relationship 
with patients’ ability carrying out daily activities. METHODS: Randomly selected  
patients (n  623) with chronic GERD symptoms treated by German ofﬁce-based 
physicians in routine clinical care completed self-administered instruments for produc-
tivity (WPAI-GERD), and symptoms (RDQ, GIS, GSRS) in assessing the response to 
treatment. WPAI-GERD includes a visual analogue scale (0–10) to rate the impairment 
of the ability to do regular daily activities in the preceding week. Reported reduction 
of daily activities was split between patients with and without, and compared using 
logistic regression, accounting for the potential confounders age and PPI-medication. 
RESULTS: Only one subscale from each three examined instrument—“diarrhoea”        
(GSRS), “impact” (GIS) and “dyspepsia” (RDQ)—were associated with reduced pro-
ductivity in daily activities in the logistic model (OR: 1.29, 3.36 and 1.46). Mean 
scores were 1.58 vs. 2.17 for subscale “diarrhoea”, 1.38 vs. 1.91 for subscale “impact” 
and 0.61 vs. 1.61 for subscale “dyspepsia”. Prescribed PPI-medication turned out to 
be independent, the odds of reduced productivity decreased with age slightly but sig-
niﬁcantly (OR 0.98). Both GSRS and RDQ have validated summary scores. “GSRS 
total” and “RDQ GERD” interacted strong with the dependent variable in the model 
(OR: 2.08 resp. 1.34). CONCLUSIONS: Validated diagnostic questionnaires for    
GERD are connected with patients’ ability carrying out daily activities. However 
subscales insufﬁciently reﬂect the perceived impact on daily life measured by reduction 
in daily activities. Generic or disease speciﬁc QoL instruments should be used in addi-
tion for a comprehensive understanding of patients’ burden in clinical practice.
PGI20
EFFECT OF SUBCUTANEOUS (SC) METHYLNALTREXONE ON PATIENT 
REPORTED CONSTIPATION SPECIFIC QUALITY OF LIFE IN A 
RANDOMIZED DOUBLE—BLIND CLINICAL TRIAL
Iyer S, Randazzo B, Tzanis E, Schulman S, Zhang H, Wang W, Manley A
Wyeth Research, Collegeville, PA, USA
OBJECTIVES: To assess the effect of subcutaneous Methylnaltrexone on patient 
reported constipation speciﬁc quality of life. METHODS: In a double blind study 469 
subjects on opioid therapy for chronic non-malignant pain and opioid-induced con-
stipation were randomized to either methylnaltrexone QD or QOD dosing or placebo 
for 4 weeks and 460 received at least 1 dose. Subjects were eligible if they had an 
opioid dose of q50 mg oral morphine equivalents/day for q2 weeks and 3 rescue free 
bowel movements (RFBMs)/week. Patients reported constipation speciﬁc quality of 
life using the Patient Assessment of Constipation—Quality of Life (PAC-QOL) ques-
tionnaire which is a validated 28—item questionnaire assessing physical discomfort 
(4 items), psychosocial discomfort (8 items), worries and concerns (11 items) and 
treatment satisfaction (5 items) on a 5-point Likert scale. Higher scores indicate poorer 
QOL. Change from baseline in mean domain and total scores were compared between 
methylnaltrexone and placebo arms on day 28 using analysis of covariance, with 
treatment group as factor and baseline score as covariate. RESULTS: Majority of the 
patients in the study were female (60%), Caucasian (90%), average age was 49 years 
and reported back pain (60%). At the end of the double blind period (day 28), a 
 signiﬁcantly greater improvement was detected in the methylnaltrexone QD dosing 
group compared to placebo for: physical discomfort (0.81 vs. 0.39;p  0.001), 
psychosocial discomfort (0.51 vs. 0.32; p  0.05), worries and concerns (0.69 vs. 
0.38; p  0.001), satisfaction (0.96 vs.0.48; p  0.001) and overall PAC-QOL 
score (0.74 vs. 0.39; p  0.001). Signiﬁcantly greater improvement in physical dis-
comfort (0.60 vs. 0.39; p  0.05), satisfaction (0.79 vs. 0.48; p  0.05) and the 
overall PAC-QOL scores (0.59 vs. 0.39; p  0.05) were found in the methylnal-
trexone QOD dosing group compared to placebo. CONCLUSIONS: Subcutaneous 
methylnaltrexone showed a signiﬁcantly greater improvement in patient reported 
constipation speciﬁc quality of life compared to placebo.
GASTROINTESTINAL DISORDERS – Health Care Use & Policy Studies
PGI21
TREATMENT OF CHRONIC HEPATITIS C WHICH DO NOT FOLLOW 
CLINICAL GUIDELINES IS INCREASING DIRECT MEDICAL COSTS
Lukac M1, Bielik J2, Zatko D3
1Faculty of Public Health at Slovak Medical University, Bratislava, Slovak Republic, 2Trencin 
University, Trencin, Slovak Republic, 3General Health Insurance, Bratislava, Slovak Republic
OBJECTIVES: This analysis evaluates economic impact of compliance with guidelines         
for treatment of Chronic Hepatitis C (CHC), where treatment decision is based on 
results of quantitative HCV RNA test (qRNA). METHODS: Retrospective insurance  
company database analysis of 879 patients with CHC was performed. There were 334 
patients tested for qRNA during the period from 1.1.2005 till 31.8.2008. Decision 
tree model was developed to evaluate treatment costs when qRNA test is used for 
treatment termination. RESULTS: In 2004 national guidelines for CHC were published,        
which recommended examination of qRNA before and 12 weeks after treatment ini-
tiation to detect early virological response (EVR) and treatment termination in case 
of negative results of EVR. In 334 patients there were 611 qRNA tests performed in 
total (150 patients had only 1 qRNA, 113 had 2 qRNA, in 55 there were 3 consecutive 
qRNA performed, 16 patients had more then 4 consecutive qRNA tests). In our model, 
omission of EVR evaluation was deﬁned as no or only one quantitative HCV RNA 
test or gap between two qRNA tests longer then 48 weeks. Omission of EVR evaluation 
was detected in 166 patients. In a decision tree model taking into account EVR results 
(followed by appropriate treatment termination) it was calculated that treatment cost 
in this group of 166 patients could be a4,013,880, while the treatment of the same 
group with omission of EVR evaluation would be a4,870,440. CONCLUSIONS: In 
analyzed group of 334 patients with HCV, there were almost 50% of cases were tre-
atment termination could not be evaluated in accordance with valid guidelines, because 
of inappropriate performance of quantitative HCV RNA tests. Calculated savings are 
a856,560 in this group of patients. Preparation and implementation of clinical practice 
guidelines in national health and drug policy could have cost saving effect.
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OBJECTIVES: Surgical management of Haemorrhoidal Disease includes Milligan-      
Morgan (MM) haemorrhoidectomy and stapled haemorrhoidopexy (PPH, Procedure 
for Prolapse and Haemorrhoids), which excises prolapsing tissues, whilst maintaining 
physiological functioning of haemorrhoidal plexus. Scope of work was to develop an 
HTA Report evaluating PPH in terms of clinical, ethical, social, organizational and 
economic impact. METHODS: Literature search on Medline/PubMed, Embase data-     
bases; analysis of the clinical course for PPH vs. MM at 3 Hospitals in Lombardia 
Region: bottom-up costing of the surgical course (surgery, hospital admission) and of 
the global course (clinical evaluation, surgical course, follow-up phase). Medical 
resources, collected by structured questionnaires, were valued (Euro 2008) on the basis 
of full hospital costs (personnel, operating theatre, hospital stay), regional outpatient 
tariffs (diagnostics), market prices (drugs, medical devices) and average per-capita 
Gross Domestic Product (working days). RESULTS: Cost analysis of the surgical     
course showed Hospital direct costs per patient/case of a2306 and a1558 respectively 
for PPH and MM (difference a748); and for the global course a2532 for PPH and 
a1781 for MM; these values exceed the ﬁxed regional DRG 158 tariff (a1209) for 
hospital reimbursement. Sensitivity analyses, based on published meta-analysis data, 
conﬁrmed the robustness of basecase results. Average regained productivity was esti-
mated to be 11.3 working days/year, with a potential social beneﬁt of a752/patient. 
The budget impact analysis, based on the difference of cost (a748) between the surgical 
courses to be applied as an extra-tariff for PPH, and on regional statistics for the 
intervention, estimated an extra-cost ranging from 1.7% to 16% over the current 
regional funding for the procedure of a9.24 mio/year.  CONCLUSIONS: Analysis of  
hospital disease management courses for haemorrhoidal disease showed the inade-
quacy of current funding for both surgical procedures, and provided an estimation of 
the effect of suggested tariff increase in order to adequately fund the local providers 
of Lombardia.
